Cookies on this site

The first volunteer has received a dose in a first-in-human trial of Oxford’s Lassa vaccine, marking a major milestone in the fight against the deadly virus. The trial, conducted by the Oxford Vaccine Group, and funded by the Coalition for Epidemic Preparedness Innovations (CEPI), will assess the safety and immune response of the ChAdOx1 Lassa vaccine. 31 people aged 18-55 will participate in the trial in total.

Lassa fever is caused by the Lassa virus, which is primarily spread by rodents and can result in serious illness including deafness, severe bleeding and even death. First discovered in the late 1960s in Nigeria, Lassa fever is endemic in West Africa. The World Health Organization (WHO) has identified Lassa fever and related viruses as priority pathogens in urgent need of research and development because they pose a significant public health risk due to their potential to cause large outbreaks. 

Experts estimate that up to 700 million people could live in regions at risk of Lassa fever by 2070, although there are currently no licensed vaccines or treatments for Lassa fever. 

Developed by researchers at the Pandemic Sciences Institute, University of Oxford, the vaccine is made using the same viral vector platform as the Oxford/AstraZeneca COVID-19 vaccine, which is estimated to have saved 6 million lives in its first year alone.   

Commenting on the launch of the trial, Professor Maheshi Ramasamy, Chief Investigator of the trial at the Oxford Vaccine Group, said:  

“Vaccines are one of the most powerful tools we have in global health: they save lives, stop outbreaks, and strengthen health systems, and so we’re delighted to start the VITAL01 Lassa fever vaccine study here in Oxford. 

Building on Oxford’s world-leading experience in developing vaccines for emerging infections and pandemics, including COVID-19, this study is a crucial step toward protecting vulnerable communities from the devastating impact of Lassa fever.” 

CEPI also supported early preclinical development of the vaccine. 

Dr Katrin Ramsaeur, Lassa Disease Programme Lead at CEPI, said:  “Today marks a transformative milestone in the fight against the deadly Lassa fever. The launch of this Lassa vaccine clinical study has been made possible by years of rigorous and innovative science, steadfast collaboration, and an unwavering commitment to global health. While there is still important work ahead, this moment brings us closer to a future where communities no longer live in fear of this devastating disease.” 

In addition to the launch of new clinical trials, plans to advance a Lassa vaccine to licensure are progressing through regional leadership and coordination by the Lassa fever Coalition. The consortium led by the West African Health Organization (WAHO), with support from CEPI and partners, is made up of West African leaders and public health experts working with vaccine makers to accelerate the development and future equitable introduction of Lassa fever vaccines across the affected region. 

Dr Virgil Lokossou, Director of Healthcare Services at WAHO said: “For more than half a century, Lassa fever has affected lives in West Africa — from our families and livelihoods to our hospitals and economies. Now, our region is taking bold steps to change that story. By working together with partners like the University of Oxford through the Lassa fever Coalition, we are leading the way in confronting this epidemic threat so that it no longer undermines our health and societies. Oxford’s vaccine candidate brings real promise for protection against this deadly disease and this clinical trial arrives at a moment when regional efforts to defeat Lassa fever are stronger than ever.”  

Similar stories

New $46M Grant Allows the University of Oxford and Boston Children’s Hospital to Lead Genetic Medicines Hub within ARIA Ecosystem

The University of Oxford and Boston Children’s Hospital, with collaboration from The Jackson Laboratory and N=1 Collaborative, have been selected to establish a new Genetic Medicines Hub, one of six research hubs within the Aligning Research to Impact Autism (ARIA) ecosystem.

Oxford-developed vaccine recommended to enter pivotal trial against deadly Bundibugyo virus

A vaccine candidate developed by scientists at the University of Oxford has been recommended to enter a pivotal Phase 2/3 clinical trial in the Democratic Republic of the Congo (DRC), in a significant step towards tackling Bundibugyo virus, a potentially deadly pathogen for which no vaccine is currently approved.

University of Oxford and BIIE launch collaboration in translational immune engineering

Researchers from the Department of Paediatrics at the University of Oxford and the Botnar Institute of Immune Engineering (BIIE) came together in Oxford last week for the inaugural scientific meeting of the new Basel–Oxford Centre for Translational Immune Engineering for Child and Adolescent Health (CTIE). The CTIE is a new collaboration between the Department of Paediatrics and the BIIE in Basel, Switzerland, designed to accelerate the translation of advances in immune engineering into new diagnostics, vaccines, therapeutics and other approaches to prevent and treat disease. Its focus is on improving the health of children and adolescents in low- and middle-income countries.

Oxford-led newborn screening pilot expanded to include all babies in England

Every newborn baby in England will be screened for spinal muscular atrophy (SMA), following the expansion of a pioneering University of Oxford-led pilot that introduced the country’s first routine test for the condition.

A New Era for Childhood Cancer Research: Professor Isidro Cortés Ciriano Appointed as Oxford's First Little Princess Trust Professor of Paediatric Oncology

The Department of Paediatrics at the University of Oxford has appointed Professor Isidro Cortés-Ciriano as its first Little Princess Trust Professor of Paediatric Oncology, marking a major milestone in a partnership dedicated to accelerating the development of new treatments for children with cancer.

Oxford University and King’s College London Join IMPACT Network Study to Advance Understanding of Profound Autism

The University of Oxford and King’s College London (King’s) have joined the Innovative Medicine and Precision Approaches to Clinical Trials (IMPACT) Network, an international collaboration of sites working together to accelerate clinical trial readiness and therapeutic development for autism through a large-scale natural history and clinical endpoint study.

Similar stories

New $46M Grant Allows the University of Oxford and Boston Children’s Hospital to Lead Genetic Medicines Hub within ARIA Ecosystem

The University of Oxford and Boston Children’s Hospital, with collaboration from The Jackson Laboratory and N=1 Collaborative, have been selected to establish a new Genetic Medicines Hub, one of six research hubs within the Aligning Research to Impact Autism (ARIA) ecosystem.

Oxford-developed vaccine recommended to enter pivotal trial against deadly Bundibugyo virus

A vaccine candidate developed by scientists at the University of Oxford has been recommended to enter a pivotal Phase 2/3 clinical trial in the Democratic Republic of the Congo (DRC), in a significant step towards tackling Bundibugyo virus, a potentially deadly pathogen for which no vaccine is currently approved.

University of Oxford and BIIE launch collaboration in translational immune engineering

Researchers from the Department of Paediatrics at the University of Oxford and the Botnar Institute of Immune Engineering (BIIE) came together in Oxford last week for the inaugural scientific meeting of the new Basel–Oxford Centre for Translational Immune Engineering for Child and Adolescent Health (CTIE). The CTIE is a new collaboration between the Department of Paediatrics and the BIIE in Basel, Switzerland, designed to accelerate the translation of advances in immune engineering into new diagnostics, vaccines, therapeutics and other approaches to prevent and treat disease. Its focus is on improving the health of children and adolescents in low- and middle-income countries.

Oxford-led newborn screening pilot expanded to include all babies in England

Every newborn baby in England will be screened for spinal muscular atrophy (SMA), following the expansion of a pioneering University of Oxford-led pilot that introduced the country’s first routine test for the condition.

A New Era for Childhood Cancer Research: Professor Isidro Cortés Ciriano Appointed as Oxford's First Little Princess Trust Professor of Paediatric Oncology

The Department of Paediatrics at the University of Oxford has appointed Professor Isidro Cortés-Ciriano as its first Little Princess Trust Professor of Paediatric Oncology, marking a major milestone in a partnership dedicated to accelerating the development of new treatments for children with cancer.

Oxford University and King’s College London Join IMPACT Network Study to Advance Understanding of Profound Autism

The University of Oxford and King’s College London (King’s) have joined the Innovative Medicine and Precision Approaches to Clinical Trials (IMPACT) Network, an international collaboration of sites working together to accelerate clinical trial readiness and therapeutic development for autism through a large-scale natural history and clinical endpoint study.